Analysis of Antihypertensive Treatment Efficacy

NCT ID: NCT00767247

Last Updated: 2010-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Analysis of antihypertensive treatment efficacy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Male or female with arterial hypertension

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* arterial hypertension
* intake of Atacand before study enrollment

Exclusion Criteria

* hypersensitivity to candesartan or any other ingredient of Atacand
* liver function impairment and/or cholestasis
* severe renal insufficiency (serum creatinine \> 265 µmol/L)
* Pregnant and lactating women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Astra Zeneca, Russia

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dmitry Zateyshchikov, MD, Prof

Role: PRINCIPAL_INVESTIGATOR

Federal State Institution of Russian President's General Management Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Arhangelsk, , Russia

Site Status

Research Site

Bryansk, , Russia

Site Status

Research Site

Domodedovo, , Russia

Site Status

Research Site

Dzerzhinsk, , Russia

Site Status

Research Site

Georgiyevsk, , Russia

Site Status

Research Site

Irkutsk, , Russia

Site Status

Research Site

Kazan', , Russia

Site Status

Research Site

Samara, , Russia

Site Status

Research Site

Severodvinsk, , Russia

Site Status

Research Site

Vidnoye, , Russia

Site Status

Research Site

Volgograd, , Russia

Site Status

Research Site

Yekaterinburg, , Russia

Site Status

Research Site

Yessentuki, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CRU-ATA-2008/1

Identifier Type: -

Identifier Source: org_study_id